The recent trend of the stock is obviously stronger than the market index, and the Xiaoyang line continues to rise moderately. But in 47 yuan, the price obviously met with resistance. In recent trading days, there has been a high level of consolidation, and the volume of transactions has not broken through, facing adjustment pressure.

From the fundamental analysis of the stock, it belongs to the leading pharmaceutical sector, and its performance has been growing steadily in the past five years. The company's profitability is strong, and its new drug research and development capabilities are among the best in China, and its future performance growth should be guaranteed. This stock is a long-term investment stock.

Based on the above analysis: if short-term speculation can be shipped first, and then transferred to the vicinity of the 30-day line before entering the market; If you invest in the stock for a long time, you can hold it firmly and don't need to pay too much attention to the adjustment of the stock. From the perspective of quantity and energy, the main funds have not fled in a big way, and the long-term trend is expected to rise. ?